Hair Loss in Patients with Inflammatory Bowel Disease

Patel, Kamal; Farrant, Paul; Sanderson, Jeremy; Irving, Peter M

doi:10.1097/mib.0b013e31828132de

Cited by 20 publications

(19 citation statements)

References 91 publications

(104 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients with active disease may experience changes in appearance due to weight loss, hair loss, or one of several cutaneous manifestations of IBD. 8,9 In addition, patients with CD may develop disfiguring fistulas to the skin and perineum. Even patient with disease in remission may experience changes in physical appearance due to the potential of corticosteroids to cause weight gain, lipodystrophy and acne, azathioprine and 6-mercaptopurine (6-MP) to cause photosensitivity, methotrexate to cause hair loss, and the tumor necrosis factor alpha (TNF)-α inhibitors to cause psoriasis.…”

Section: Introductionmentioning

confidence: 99%

Body Image Dissatisfaction in Patients with Inflammatory Bowel Disease

Saha

Zhao

Shah

et al. 2015

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

Background Despite the fact that the inflammatory bowel diseases (IBD) and their treatments may affect physical appearance, the effect of IBD on body image is poorly understood. The aims of this study were to determine whether body image dissatisfaction (BID) changes over time in patients with IBD and to examine the demographic and disease-related variables associated with decreased body image. Methods Adults aged 18 and above in the Ocean State Crohn's and Colitis Area Registry with at least 2 years of follow-up were eligible for this study. All patients were enrolled within 6 months of IBD diagnosis and followed prospectively. BID was assessed using a modified version of the Adapted Satisfaction With Appearance (ASWAP) questionnaire. Total ASWAP scores and 2 sub-scores were calculated. To assess for changes over time, general linear models for correlated data were used for continuous outcomes and generalized estimating equations were used for discrete outcomes. Results Two hundred seventy-four patients were studied. BID was found to be stable over time among men and women with IBD despite overall improvements in disease activity. No differences were found in BID according to IBD subtype. Female gender, greater disease activity, higher symptom burden, longer duration of steroid use, dermatologic and musculoskeletal manifestations of IBD, and ileocolonic disease location among patients with Crohn's disease were associated with greater BID. Greater BID was associated with lower health-related quality of life (HRQOL). Conclusions BID remains stable in an incident cohort of IBD despite improved disease activity and is associated with lower HRQOL

show abstract

Section: Introductionmentioning

confidence: 99%

Body Image Dissatisfaction in Patients with Inflammatory Bowel Disease

Saha

Zhao

Shah

et al. 2015

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

show abstract

“…Identifying an exact cause may be difficult as hair loss has been associated with concomitant autoimmune diseases (alopecia areata, telogen effluvium), in up to 60% association with acute or chronic flares of IBD [171,172], as well as IBD medications, such as azathioprine and infliximab [173][174][175]. However, the cross-sectional study and a case report suggest a protective effect of mesalamines, azathioprine, and anti-TNFs [171,173].…”

Section: Alopeciamentioning

confidence: 87%

Symptom management in inflammatory bowel disease

Abraham

2015

Expert Review of Gastroenterology & Hepatology

View full text Add to dashboard Cite

Patients with inflammatory bowel disease can present with a wide variety of symptoms. Most are related to disease activity and should be managed with appropriate medical therapy for inflammatory bowel disease. However, some patients may develop symptoms due to the side effects of the medications, or due to immunosuppression. In these cases, the offending medications should be discontinued until resolution of the symptoms and a few may be able to restart therapy. Symptoms can also occur as an extraintestinal manifestation of the disease or due to concomitant autoimmune-mediated disorders. Regardless of the etiology, symptoms should be addressed promptly with immediate evaluation and appropriate therapy, as a delay may lead to permanent sequela.

show abstract

“…Additionally, 2% or 5% topical minoxidil and general hair care measures (avoid hair pulling, dyes, and relaxers) are recommended. The hair loss is reversible, and psychological counseling is advised [2,3,5,[28][29][30][31].…”

Section: Anagen Effluviummentioning

confidence: 99%

Alopecias Due to Drugs and Other Skin and Systemic Disorders

Guzmán-Sánchez¹,

Asz-Sigall²

2015

Alopecias - Practical Evaluation and Management

View full text Add to dashboard Cite

In this chapter, we will discuss the most common alopecias due to drugs and other skin and systemic disorders. The following hair disorders will be analyzed: telogen effluvium (acute and chronic); anagen effluvium; folliculotropic mycosis fungoides; and folliculitis due to bacteria, fungi, parasites, human immunodeficiency virus disease, lupus erythematosus, and sarcoidosis. We will cover topics including the epidemiology, etiology, clinical picture, and diagnosis of and current treatments for each disease.

show abstract

Hair Loss in Patients with Inflammatory Bowel Disease

Abstract: The potential causes of hair loss in IBD are protean, although its prevalence is unknown. A practical guide to assessing and managing patients with hair loss in IBD is presented.

Cited by 20 publications

References 91 publications

Body Image Dissatisfaction in Patients with Inflammatory Bowel Disease

Body Image Dissatisfaction in Patients with Inflammatory Bowel Disease

Symptom management in inflammatory bowel disease

Alopecias Due to Drugs and Other Skin and Systemic Disorders

Contact Info

Product

Resources

About